Objectives: Here we sought to describe the real-life usage of micafungin in a UK tertiary referral hospital.
Methods: A prospective, non-interventional, observational surveillance study was performed.
Results: Micafungin was commenced in 174 courses involving 148 patients to treat invasive candidiasis and candidaemia (132 courses) and aspergillosis in situations where alternatives such as voriconazole or liposomal amphotericin B could not be used (42 courses).
Invasive fungal infections (IFI) are an emerging problem worldwide with invasive candidiasis and candidemia responsible for the majority of cases. This is predominantly driven by the widespread adoption of aggressive immunosuppressive therapy among certain patient populations (e.g.
View Article and Find Full Text PDF